These reactions should not discourage patients from getting the vaccine, researchers say.
- Mass General study identifies key predictors of COVID-19 mortality among different age groups from patient longitudinal medical records.
- Predictive analytics based on electronic health records could prove valuable in allocating and distributing limited resources in the time of a pandemic.
Hossein Estiri, PhD
By combining computational methods and clinical expertise, we developed a set of models to forecast the most severe COVID-19 outcomes based on past medical records, and to help understand the differences in risk factors across age groups.
Laboratory of Computer Science, Massachusetts General Hospital
BOSTON – Medical histories of patients collected and stored in electronic health records (EHR) can be rapidly leveraged to predict the probability of death from COVID-19, information that could prove valuable in managing limited therapeutic and preventive resources to combat the devastating virus, researchers from Massachusetts General Hospital (MGH) have found. In a study published in npj Digital Medicine, the team described how artificial intelligence (AI) technology enabled it to identify factors such as age, history of pneumonia, gender, race and comorbidities like diabetes and cancer as predictors of poor outcomes in COVID-19 patients.
“By combining computational methods and clinical expertise, we developed a set of models to forecast the most severe COVID-19 outcomes based on past medical records, and to help understand the differences in risk factors across age groups,” says co-lead author Hossein Estiri, PhD, an investigator in the Laboratory of Computer Science at MGH and an assistant professor of Medicine at Harvard Medical School (HMS). “Many prior studies have isolated small subsets of EHR data from after the infection, but ours is the first and largest to use entire historical medical records to try to untangle the role of age as the most important risk factor for COVID adverse outcomes.”
The analytics/medical team drew on the COVID-19 “datamart” that had been created by hospital system Mass General Brigham for research, a repository of frequently refreshed longitudinal data on COVID-19 patients from across the system. Using electronic medical records from more than 16,000 such patients, the MGH team applied a computational algorithm — with a human expert in the loop — to identify 46 clinical conditions representing potential risk factors for death after a COVID-19 infection. “Despite relying on only previously documented demographics and comorbidities, our models demonstrated performance comparable to more complex prognostic models requiring an assortment of symptoms, laboratory values and images gathered at the time of diagnosis or during the course of the illness,” notes Zachary Strasser, MD, co-lead author and postdoctoral fellow at MGH.
The MGH study found age to be the most important predictor of mortality in COVID-19 patients. A history of pneumonia was also identified by the study as a significant risk factor, as were histories of diabetes with complications, and cancer (particularly breast and prostate) among COVID-19 patients between the ages of 45 and 65. In patients between 65 and 85, diseases affecting the pulmonary system — including interstitial lung disorders, chronic obstructive pulmonary disease (COPD), lung cancer, and a history of smoking – were strong predictors of poor outcomes. Comorbidities registering the highest odds ratios for death irrespective of age were chronic kidney disease, heart failure, abdominal aortic aneurysm, hypertension and aortic valve disease.
As for gender, the study found females to be at lower risk of death from COVID-19. Even after adjusting for age and chronic diseases, the researchers learned that women benefited from an unknown form of underlying protection against the worst outcome of the viral infection. In their overall model, researchers did not find evidence that a certain race or ethnicity altered the odds of mortality after contracting COVID-19. They did find in the oldest cohort of patients, however, that being African American was associated with a higher chance of mortality.
The sheer volume of EHR information and its marriage to predictive analytics becomes particularly important during a pandemic when access to large-scale, clinical trial grade data is not practical, emphasizes Shawn Murphy, MD, PhD, senior author and chief research informatics officer at Mass General Brigham. “The ability to quickly utilize data that has already been collected across the country to compute individual-level risk scores,” he says, “is crucial for effectively allocating and distributing resources, including prioritizing vaccination among the general population.”
The researchers are from the MGH Laboratory of Computer Science; the Department of Biomedical Informatics at HMS; and the MGH Department of Neurology.
The study was supported by the National Human Genome Research Institute and the National Library of Medicine.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Mar | 2 | 2021
Experts offer guidance to reduce false positive tests and avoid unnecessary biopsies.
- Press Release
- Feb | 26 | 2021
Two new models boost accuracy in assessing which COVID-19 patients face the greatest risk of mechanical ventilation and death
A pair of novel calculators could help hospitals predict patient outcomes and better allocate scarce resources such as ICU beds and ventilators.
- Press Release
- Feb | 24 | 2021
Radiologists offer an approach to avoid confusion among patients and clinicians.
- Press Release
- Feb | 18 | 2021
Researchers at the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital show that levels of specific antibodies developed in the immune response may influence COVID-19 outcomes in both children and adults.
- Press Release
- Feb | 16 | 2021
Ragon and BWH researchers collaborate with SpaceX to identify humoral immune features which may track with lasting protection against SARS-CoV-2
Antibody testing may, as a study recently published in the journal Nature Communications shows, hold the key to understanding the immune response to the virus.